Public comments have an important role in the MRTP review process, the agency said, and the FDA recognizes that TPSAC meetings provide the public with an opportunity to present information to TPSAC members.
The agency asks that the public refer to the Federal Register notice for instructions on how to submit public comments to TPSAC. Requests to present an oral comment at the September 2018 meeting must be received by Aug. 16. Written comments related to the TPSAC meeting must be received by Aug. 29.
These deadlines apply only to the TPSAC meeting and do not apply to the public docket for Reynolds’ MRTP applications. There is currently no deadline for public comments on these applications.
Photo courtesy of Thinkstock